Detalhe da pesquisa
1.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Lancet
; 394(10216): 2271-2281, 2019 12 21.
Artigo
Inglês
| MEDLINE | ID: mdl-31868632